Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover study

233-OR: Ultra-Rapid Lispro (URLi) Demonstrates Similar Time-in-Target Range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System

(2020) BRUCE W. BODE et al.   DIABETES

231-OR: Phase I Study Investigating the PD, PK, and Safety of AT247 in Comparison with Novorapid and Fiasp

(2020) THOMAS R. PIEBER et al.   DIABETES

Fast-Acting Insulin Aspart Use with the MiniMed™ 670G System

(2020) Liana J Hsu et al.   Diabetes Technology & Therapeutics

One Year Clinical Experience of the First Commercial Hybrid Closed-Loop

(2019) Rayhan A. Lal et al.   DIABETES CARE

Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial

(2019) Klemen Dovc et al.   DIABETES CARE

Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes

(2019) Sue A. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis

(2018) Eleni Bekiari et al.   BMJ-British Medical Journal

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis

(2018) Eleni Bekiari et al.   BMJ-British Medical Journal

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

(2018) Martin Tauschmann et al.   LANCET

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

(2016) Tim Heise et al.   CLINICAL PHARMACOKINETICS

Hypoglycemia in Type 1 Diabetes Mellitus

(2010) Philip E. Cryer   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA